Clinical trial · Interventional
Hepatic Hilar Nerve Block Versus Sham in Pain Control During Liver Ablation and TACE Procedures
Prospective Randomized Double-Blind Study of Pain Control With Hepatic Hilum Nerve Block Versus Sham Procedure For Hepatic Chemoembolization or Radiofrequency Ablation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is aimed at assessing the effectiveness of a novel liver specific nerve block in improving pain control during painful liver interventional radiology procedures including liver tumoral ablation and trans arterial chemoembolization, two procedures aimed at controlling liver tumors, but that can be associated with significant pain. This novel hepatic specific nerve block was designed by us and initial retrospective results suggests it might help in controlling such liver procedural derived pain. The study was designed to compare the liver block to a sham procedure in a blinded context and to follow the participants over three days post-procedure to asses for pain levels.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Pain Control | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Hepatic Hilar Nerve Block Needle placement | Procedure | — | UNRESOLVED |
| Injection of normal saline in the hepatic hilum for the sham procedure | Drug | — | UNRESOLVED |
| Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Hepatic hilar nerve block in ablation patients
- description
- 15ml of 0.7% ropivacaine will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
- interventionNames
- Procedure: Hepatic Hilar Nerve Block Needle placement
- Drug: Injection of Ropivacaine in the hepatic hilum for the hepatic hilar nerve block
- type
- PLACEBO_COMPARATOR
- label
- Placebo procedure in ablation patients
- description
- 15ml of sterile normal saline will be injected at the hepatic hilum anterior to the portal vein as close to the bifurcation as possible under US guidance using a 21g needle prior to the Ablation procedure.
- interventionNames
- Procedure: Hepatic Hilar Nerve Block Needle placement
- Drug: Injection of normal saline in the hepatic hilum for the sham procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients referred to the Interventional Radiology department and approved for a chemo-embolization or radiofrequency ablation of malignant primary or secondary liver tumour. 2. At least 18 y.o. Exclusion Criteria: 1. Patients in whom the vascular anatomy prevents safe access to the hepatic hilum or patients in whom general anaesthesia was performed. 2. Patients who have known allergy to any anaesthetic agent in the regular protocol (fentanyl, midazolam, ropivacaine). 3. Patients with signs of skin infection at the entry site of the needle used to perform the nerve block 4. Patients with signs of infection such as fever or acute increase in wight blood cell count. 5. Patients with uncorrectable abnormal coagulation status (INR \>1.5 and platelets \< 50000 without use of anticoagulation agents). 6. Patients with pre-existing conditions, which, in the opinion of the investigator, interfere with the conduct of the study (these reasons will be recorded) 7. Patients, who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires. 8. Patients with a mental state that may preclude completion of the study procedure or are unable to provide informed consent.
References
Publications (0)
Data not yet available